<SEC-DOCUMENT>0001193125-21-106610.txt : 20210406
<SEC-HEADER>0001193125-21-106610.hdr.sgml : 20210406
<ACCEPTANCE-DATETIME>20210405184502
ACCESSION NUMBER:		0001193125-21-106610
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210405
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210406
DATE AS OF CHANGE:		20210405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cidara Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001610618
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				461537286
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36912
		FILM NUMBER:		21807312

	BUSINESS ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-752-6170

	MAIL ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	K2 THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20140611
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d140370d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cdtx="http://imetrix.edgar-online.com/20210405" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-04-05_to_2021-04-05">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-04-05_to_2021-04-05">0001610618</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="cdtx-20210405.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-04-05_to_2021-04-05"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-05</xbrli:startDate> <xbrli:endDate>2021-04-05</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-04-05_to_2021-04-05">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-04-05_to_2021-04-05" format="ixt:datemonthdayyearen">April 5, 2021</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2021-04-05_to_2021-04-05">Cidara Therapeutics, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-04-05_to_2021-04-05" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-04-05_to_2021-04-05">001-36912</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-04-05_to_2021-04-05">46-1537286</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction of</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Incorporation or Organization)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification Number)</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-04-05_to_2021-04-05">6310 Nancy Ridge Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2021-04-05_to_2021-04-05">Suite 101</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-04-05_to_2021-04-05">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-04-05_to_2021-04-05" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-04-05_to_2021-04-05">92121</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-04-05_to_2021-04-05">(858)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-04-05_to_2021-04-05">752-6170</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-04-05_to_2021-04-05" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-04-05_to_2021-04-05" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-04-05_to_2021-04-05" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-04-05_to_2021-04-05" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-04-05_to_2021-04-05">Common Stock, Par Value $0.0001 Per Share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-04-05_to_2021-04-05">CDTX</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-04-05_to_2021-04-05" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-04-05_to_2021-04-05" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;5, 2021, Cidara Therapeutics, Inc. (the &#8220;Company&#8221;) held a conference call to discuss the Company&#8217;s previously announced exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, Inc. The conference call transcript is attached hereto as Exhibit 99.1. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">Exhibit<br />No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d140370dex991.htm">Transcript of Cidara Therapeutics conference call, held April&#160;5, 2021. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:47%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:46%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Cidara Therapeutics, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: April&#160;5, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey L. Stein</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Jeffrey L. Stein</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">President and Chief Executive Officer <br />(Principal Executive Officer)</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d140370dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g140370dsp1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CORPORATE PARTICIPANTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Tracey
Sebastian, </B><I>LifeSci Advisors</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Jeff Stein, </B><I>President and Chief Executive Officer</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Jamie Levine, </B><I>Chief Financial Officer</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Paul Daruwala, </B><I>Chief
Operating Officer</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CONFERENCE CALL PARTICIPANTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Louise Chen,
</B><I>Cantor Fitzgerald</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Joseph Stringer, </B><I>Needham</I><I></I><I>&nbsp;&amp; Company</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nathan Weinstein, </B><I>Aegis Capital</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Robert Driscoll, </B><I>Wedbush
Securities</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRESENTATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Good morning, ladies and gentlemen, and welcome to the Cidara Therapeutics Business Update Call. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">At this time, all participants are in a listen-only mode. A brief
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">question-and-answer</FONT></FONT> session will follow the formal presentation. If anyone should require Operator assistance during the conference, please press star, zero on your
telephone keypad. As a reminder, this conference is being recorded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">It is now my pleasure to introduce your host Tracey Sebastian with LifeSci
Advisors. Thank you, Ms.&nbsp;Sebastian. You may begin. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Tracey Sebastian </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Thank you, Operator, and thank you all for joining us today. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">With me on today&#146;s call are Jeff Stein, President and Chief Executive Officer; Jamie Levine, Chief Financial Officer; and Paul Daruwala, Chief
Operating Officer of Cidara Therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This morning, Cidara issued a news release announcing that it has entered into a collaboration agreement
with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson&nbsp;&amp; Johnson, to develop and commercialize Cidara&#146;s Cloudbreak antiviral conjugates, or AVCs, for the prevention and treatment of seasonal and
pandemic influenza. The collaboration agreement was facilitated by Johnson&nbsp;&amp; Johnson Innovation. Please note, the effectiveness of this agreement is subject to the expiration or earlier termination of all applicable waiting periods under
the Hart-Scott-Rodino Antitrust Improvements Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U>
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g140370dsp1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Before I turn the call over to Jeff, I would like to note that all of the information discussed on the
call today is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that during this call Management will be making forward-looking statements. Actual results could differ materially from those
stated or implied by forward-looking statements due to risks and uncertainties associated with the Company&#146;s business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in Cidara&#146;s SEC
filings, including its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">I would also like to point out that the content of this
conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, April&nbsp;5, 2021. Cidara undertakes no obligation to revise or update any forward-looking statements to reflect events or
circumstances after the date of this conference call. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">I will now turn the call over to Jeff Stein, President and CEO of Cidara. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Jeff Stein </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Good morning everyone, and thank you for joining
our call. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">We are very excited to announce today that we have entered into an exclusive worldwide license and collaboration agreement with Janssen
Pharmaceuticals, a part of Johnson&nbsp;&amp; Johnson, to develop and commercialize Cidara&#146;s Cloudbreak Antiviral Conjugates, or AVCs, for the prevention and treatment of seasonal and pandemic influenza. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Our Cloudbreak antiviral platform represents a potentially transformational approach to prevent and treat viral infections, from which we are creating a
new generation of immunotherapeutic antiviral conjugates for influenza, RSV, HIV, SARS-CoV2 and other viruses. AVCs are a novel class of drugs that couple potent antivirals to a human antibody fragment, or Fc. These long-acting AVCs directly inhibit
viral replication while simultaneously engaging the immune system, and may offer significant advantages over vaccines and monoclonal antibodies. Our Influenza AVCs, such as CD388, are designed for rapid onset and have the potential to deliver potent
universal flu protection for an entire flu season with a single dose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Under the terms of the agreement with Janssen, Cidara will be responsible for
the development and key aspects of manufacturing of our lead influenza AVC, CD388, into the clinic and through the first Phase 2 clinical trial, and Janssen will be responsible for and will fund late-stage development, manufacturing, registration,
and worldwide commercialization. Janssen will reimburse Cidara for the costs incurred in conducting research and development of CD388 under an agreed research plan and budget. Cidara will receive an upfront payment of $27&nbsp;million and will be
eligible to receive up to an additional $753&nbsp;million, which consists of budgeted R&amp;D funding, as well as development, regulatory and commercial milestones. In addition, Cidara will receive tiered royalties on worldwide sales in the <FONT
STYLE="white-space:nowrap">mid-to</FONT> high-single digits, and will have the option to <FONT STYLE="white-space:nowrap">co-detail</FONT> CD388 in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This collaboration represents a tremendous achievement for Cidara and validates the significant potential of our Cloudbreak AVC platform, as well as the
incredible innovation and efforts of the Cidara team. Leveraging Janssen&#146;s infrastructure and commercial capabilities will be invaluable to the expeditious development of CD388 for influenza on a global scale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Currently, we believe there is a significant unmet need in the influenza landscape and large market opportunity. We all know influenza as a contagious
infection that can cause severe illness, and sometimes it results in death, which is why the CDC recommends that all people over six months of age receive the flu vaccine each year. A 2018 CDC study estimated that about 8% of the U.S. population, or
more than 25&nbsp;million Americans, get sick from the flu in a typical year, even with current vaccination efforts, resulting in a total economic burden of over $11&nbsp;billion per year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g140370dsp1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Current treatment options are often ineffective and viral resistance to existing drugs has been
observed. Moreover, current flu vaccines, while critical and still our best defense to date, have two well-known limitations: they don&#146;t cover all strains of flu, and they don&#146;t cover all people who receive the vaccine. To the first point,
vaccines typically cover only three to four of the dozens of flu strains that could become prevalent during a given flu season. The vaccine strains are selected six months before the flu season and, due to antigenic drift, can become less
susceptible to the vaccine over time. To my second point, of the 49% of Americans who historically obtain an annual influenza vaccine, about 60% do not adequately respond and remain at risk of getting the flu. In fact, vaccine effectiveness for the
2018-2019 flu season was estimated to be only 29%, with effectiveness rates as low as 12% in people over 65. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Importantly, we designed our influenza
AVC, CD388, to address the shortcomings in both the prevention and treatment settings. AVCs are not vaccines, monoclonal antibodies, or traditional therapeutics, but rather they are potent long-acting drugs. As such, they are designed to offer
several advantages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">First, in the prevention setting, our preclinical data support the potential for CD388 to provide universal protection from all
flu strains tested, both A and B, including both seasonal and pandemic strains. In addition, because AVCs are long-acting drugs that do not require an immune response as a vaccine does, they have demonstrated efficacy in severely immunocompromised
mouse infection models, which are intended to represent high-risk populations such as the elderly or immune-compromised. As a result, CD388 has the potential to fulfill our vision that a single dose, given subcutaneously or intramuscularly, could
provide universal protection against all strains for all people for an entire flu season. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">An additional advantage of AVCs is the time required to
achieve protection. Vaccines can have a delay of up to 14 days until they are fully protective, while AVCs are expected to take effect nearly immediately. AVCs also have potential advantages over monoclonal antibodies, which typically have high
production costs and limited spectrum that can prohibit their utility for disease prevention in broad populations. Flu AVCs are highly active against A and B, whereas monoclonal antibodies currently in development are only active against A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Flu AVCs also have advantages in the treatment setting. Importantly, the efficacy window of today&#146;s flu treatment options is only about 48 hours,
not nearly long enough for most people to benefit from existing therapeutic options. Our preclinical studies demonstrate that flu AVCs may extend that treatment window by up to 24 hours longer, giving AVCs the potential to drastically improve
patient responses. Additional preclinical studies demonstrate that flu AVCs have a lower resistance potential compared to approved influenza treatments, as well as near-immediate protective effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">As a result of these data, we believe AVCs have the potential for fast-acting universal treatment of Influenza A and B, including all major clinically
characterized drug-resistant seasonal and pandemic strains. Collectively, flu AVCs such as CD388 have the potential to protect all high-risk groups from all known influenza strains from both a prevention and treatment standpoint, while remaining a
cost-effective and scalable option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In terms of upcoming milestones, we have a very active year planned for the CD388 program. We are currently
completing <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for CD388 and expect to file an IND by the end of this year, and to subsequently initiate a Phase 1 study in early 2022. Concurrently, we are scaling manufacturing with a
leading contract manufacturer and will direct aspects of CD388 manufacturing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g140370dsp1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In summary, we believe the Janssen collaboration we are announcing today validates our vision of the
game-changing potential of flu AVCs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">I&#146;d like to turn now to address the opportunities we see in our broader Cloudbreak antiviral platform
programs which are not presently partnered. I mentioned earlier that the foundational concept of our Cloudbreak platform is to generate long-acting, antiviral drugs, by linking potent antivirals to a human antibody fragment. With this modular
approach we can swap out the influenza antiviral targeting moiety for a different small molecule or peptide antiviral directed against a different pathogen and thereby generate AVCs to target other viral diseases with our immunotherapeutic approach.
Our current efforts are focused on RSV, HIV and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2.</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">I&#146;ll begin with respiratory syncytial virus, or RSV. RSV is the second largest cause of death in children under one year of age worldwide, second
only to malaria. There is a significant unmet need for both seasonal and long-term prevention and treatment of RSV for the very young, the elderly and those with weaker immune systems, and currently there is no vaccine for RSV. We believe that there
is an unmet need for a therapy can provide broad-spectrum viral coverage with a long duration of action and can also protect high-risk individuals. The encouraging preclinical efficacy of influenza AVCs suggests that the Cloudbreak AVC platform has
the potential to address this deficiency in the current landscape for RSV. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Given Janssen&#146;s significant research and commercial presence in the
field of respiratory viral infections, including RSV, Cidara has granted Janssen an exclusive right of first negotiation, for a limited period of time, to negotiate for and enter into a separate collaboration for the research and development of AVCs
addressing RSV. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Moving on to our HIV program, like RSV there is no vaccine for HIV, and long-term prevention and maintenance remain priorities. HIV
has a critical unmet need for long-acting, effective drugs and we see the market shifting in that direction. Our RSV, HIV, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> programs will benefit from the
learnings from our flu AVC program to accelerate their advancement. We look forward to sharing additional preclinical data on these programs in the near future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Finally, we are also actively considering other viral diseases to target with our Cloudbreak approach based on technical, clinical and commercial
attributes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Notwithstanding the focus and excitement today regarding our flu AVCs and our collaboration with Janssen, there is more to Cidara than
the Cloudbreak antiviral platform. Our most advanced infectious disease program focuses on the attractive systemic antifungal market and we continue to advance our novel long-acting echinocandin, rezafungin, through two Phase 3 clinical trials. The
first is the ReSTORE trial, which addresses the treatment of candidemia and invasive candidiasis, and the second is our ReSPECT prophylaxis trial focused on the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow
transplant. Rezafungin, if approved, could transform the standard of care for the treatment and prevention of invasive fungal infections and has the potential to be the first new antifungal in over a decade indicated for both first-line Candida
treatment and first-line antifungal prophylaxis. These two Phase 3 trials could position Cidara and rezafungin squarely within both the infectious disease and hematology settings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The rezafungin program is validated by our partnership with Mundipharma, through which Cidara retains rights for the U.S. and Japan, whereas Mundipharma
will commercialize rezafungin in all other regions. As a reminder, we expect topline results from the Phase 3 ReSTORE treatment trial by the end of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">As I begin to wrap up my prepared comments, I&#146;d like to address the positive financial impact of this collaboration on Cidara&#146;s future
operations. We expect that our strengthened balance sheet, both from the upfront payment and ongoing R&amp;D funding from the Janssen collaboration, as well as the ongoing support </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g140370dsp1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">
from Mundipharma for our rezafungin Phase 3 clinical trials, provides us with the cash resources necessary to fund our activities past the expected IND filing for CD388 and topline data for the
ReSTORE Phase 3 trial. Importantly, both our rezafungin and Cloudbreak platforms are now validated by key strategic partnerships with Mundipharma and Janssen, respectively. On a combined basis, these two collaborations have the potential to provide
us up to $1.3&nbsp;billion in R&amp;D funding and milestone payments, as well as additional royalty payments on commercial sales in the coming years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In conclusion, the collaboration with Janssen we have announced today is just the beginning of what we believe will be an extraordinarily dynamic time
for Cidara. In the past two years, we have entered into two lucrative and validating strategic relationships that financially support our research and development efforts and expand our mission globally. These collaborations are a testament to the
credibility of the Cidara team and the compelling potential of, and significant market opportunities for rezafungin and our Cloudbreak AVCs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">With
multiple near-term catalysts and attractive long-term potential, Cidara is well-positioned to become an established leader in the antifungal and antiviral therapeutic areas. We are committed to advancing our diverse pipeline of assets to transform
the current standard of care for patients and we look forward to providing updates on our progress in the coming months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">With that, I&#146;d like
to turn the call back over to the operator so we can address your questions. Operator? </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Thank you. Ladies and gentlemen, at this time we will conduct a <FONT STYLE="white-space:nowrap">question-and-answer</FONT> session. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Thank you. Our first questions come from the line of Louise Chen with Cantor Fitzgerald. Please proceed with your questions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Louise Chen </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Hi. Congratulations on the deal and thanks for
taking my questions here. I have a few. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The first question I have for you is could your AVC be developed to treat both influenza and SARS-CoV2?
Then, secondly, when do you expect to have the Phase 2 results and what will that trial design look like? Then lastly, what is the efficacy or anticipated efficacy of your AVC versus the current vaccines? I know you talked about the efficacy rate of
those vaccines, but where could your efficacy rate come out? Thank you. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Jeff Stein </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Let me address the last question first, Louise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">As
we&#146;ve seen historically with flu vaccines, in the 2018-2019 flu season that was about 29% overall with as low as 12% in the population over 65. We have yet to find&#151;and when I say we I mean we, our partner, NIH who have been testing our flu
AVCs including CD388&#151;we have yet to find a flu strain that is not susceptible to CD388 at the expected efficacious exposure. We&#146;re very optimistic that this could be in fact a better solution, especially in times of a pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Can you remind me of the first question, Louise? </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g140370dsp1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Louise Chen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Yes, sure. Does your product or could you make your AVC so that it could protect against both influenza and SARS-CoV2? </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Jeff Stein </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">We have contemplated that. This is a modular
approach and because of the way that we can engineer the Fc, we can have a single Fc that can contain two different moieties that target two different viruses. We haven&#146;t disclosed any detail on that to date, but it&#146;s something that we
certainly have contemplated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Louise Chen </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Okay. And what
about your Phase 2 result timing? When do you think you&#146;ll see that? </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Jeff Stein </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Well, we expect to file an IND by the end of this year, and we then expect to start Phase 1 shortly thereafter. Historically, the types of single and
multiple ascending dose Phase 1s that we contemplate for other indications typically take 9 to 12 months, and after evaluating the data we&#146;ll determine the nature of the Phase 2 study and we&#146;ll determine the length of time that should take
at that point in time, but it will be driven largely off of the results of the Phase 1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Louise Chen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Thank you. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Thank you. Our next questions come from the line of Joseph Stringer with Needham&nbsp;&amp; Company. Please proceed with your questions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Joseph Stringer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Hi everyone. Good morning and congrats on
the collaboration and thanks for taking our question. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">I was just curious what the&#151;you have 377 and 388 AVC programs. What are sort of the
determining factors with 388 as the lead in your discussions with Janssen? Was it sort of the potential for the longer duration or immune engagement, or some of the discussions around that? Thank you. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Jeff Stein </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Yes, you&#146;ve got that right. CD377 and CD388
only differ by the nature of the Fc domain, with CD388 being longer acting. We sought to prioritize CD388 for that attribute. CD377 also falls under this agreement and there is a potential to develop that separately. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Joseph Stringer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Okay, great. Thanks for taking our question.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Jeff Stein </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Okay. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g140370dsp1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Thank you. Our next questions come from the line of Nathan Weinstein of Aegis Capital. Please proceed with your questions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nathan Weinstein </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Good morning and congratulations on the
announcement today. Very interesting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">I was just hoping to ask a question about the flu market. In light of COVID, the flu season was rather benign
but just maybe some thoughts about how it could develop in the future. Do you expect sort of a reversion to the mean in terms of flu incidence? </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Jeff Stein
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Yes, Nathan. Let me hand that one over to Paul Daruwala, our COO. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Paul Daruwala </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Thanks, Nathan. As you know, historically the
flu market has been obviously quite interesting, mostly dominated by vaccines So if you&#146;ve got 49% of the U.S. population that gets a vaccine every year that&#146;s almost 150&nbsp;million people. The CDC still recommends&#151;no change such
that everyone over the age of six months gets a vaccine; that&#146;s in the U.S. alone so you still have quite a tremendous market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">I think what
we&#146;ve seen this past year, obviously with social distancing and people wearing masks, the change has been quite dramatic. I think what all experts anticipate and we agree is that the flu market will return very similar to the way it has in
previous years and some experts may say that it&#146;s actually going to be worse when masks lift; much of that because the antigens aren&#146;t circulating in the population as they would have otherwise, you may even have a rebound. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Jeff Stein </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">I would add to that Nathan is that before the
coronavirus hit us last year, the major worry was pandemic influenza and so that was one of the reasons why we really prioritized our influenza program. Nobody believes that this will not come back, and to Paul&#146;s point, the absence of
circulating antigens today actually could lead to a worse flu season coming and that&#146;s one of the reasons why we sought to partner with Janssen with their capabilities in conducting very rapid clinical trials in large populations. We
couldn&#146;t think of a better partner to partner with. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nathan Weinstein </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">That&#146;s great. Thank you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">I just
wonder&#151;and this is conjecture&#151;if vaccination rates won&#146;t actually go up more because Americans have had this experience with going in and getting the COVID vaccine, so maybe the vaccination rates for flu in the future seasons will be
higher than they were in the past. That obviously helped the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Just a question on the AVCs and manufacturing. Obviously it&#146;s a really
unique and interesting structure. Can you just talk about if you expect manufacturing capability to be in place at the future when you need it? </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g140370dsp1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Jeff Stein </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">That&#146;s certainly the plan. We are currently directing manufacturing and at some point in the development program Janssen will take over the
responsibilities for manufacturing. Certainly they have the infrastructure to do that on a very large basis globally. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nathan Weinstein </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Okay, great. Thank you, guys, for taking my questions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Operator
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Thank you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Our next questions come from
the line of Robert Driscoll with Wedbush. Please proceed with your questions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Robert Driscoll </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Thanks. Good morning, guys, and thanks for taking the question. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">I think you mentioned it quickly on the call, but can you remind us how the RSV Cloudbreak candidate is designed and how you might expect the
development of CD377, CD388 might <FONT STYLE="white-space:nowrap">de-risk</FONT> that program? Thanks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Jeff Stein </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Yes, Robert. We haven&#146;t disclosed the details of the RSV program. Certainly the preclinical data we see today are hot and very compelling, and so
this is one of the reasons why we have provided Janssen a right of first negotiation for a limited period of time to advance that program. Because as with influenza, that would be a very broad development program in large populations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Robert Driscoll </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Got it. Thanks very much and congratulations
on the collaboration today. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Jeff Stein </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Thank you,
Robert. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Operator </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Thank you. There are no further
questions at this time. I would like to hand the call back over to Jeff Stein for any closing comments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Jeff Stein </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Thank you all for joining our call today. We are extremely pleased to share the details of this important transaction, as well as review the significant
near-term opportunities that lie ahead for both Cloudbreak and rezafungin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">We appreciate your continued interest in and support of Cidara. Have a
good day, everyone. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Operator</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Thank you for joining us
today. This does conclude this morning&#146;s conference call. You may disconnect your lines at this time. Have a great day. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cdtx-20210405.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 4/6/2021 2:38:52 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:cdtx="http://imetrix.edgar-online.com/20210405"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://imetrix.edgar-online.com/20210405"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20210405_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20210405_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cdtx-20210405_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 4/6/2021 2:38:52 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cdtx-20210405_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 4/6/2021 2:38:52 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cdtx-20210405.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g140370dsp1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g140370dsp1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M[9=F)_:R_P#/I<_]\K_C1[/S#VR[,/[63_GTN?\ OE?\:/9^8>V79A_:R?\
M/I<_]\K_ (T>S\P]LNS#^UT_Y]+G_OE?\:/9^8>V79A_:Z?\^ES_ -\K_C1[
M/S#VR[,/[73_ )]+G_OE?\:/9^8>V79A_:Z?\^ES_P!\K_C1[/S#VR[,/[73
M_GTN?^^5_P :/9^8>V79A_:Z?\^ES_WRO^-'L_,/;+LP_M=/^?2Y_P"^5_QH
M]GYA[9=F']KI_P ^ES_WRO\ C1[/S#VR[,/[73_GTN?^^5_QH]GYA[9=F']K
MI_SZ7/\ WRO^-'L_,/;+LP_M=/\ GTN?^^1_C1[/S#VR[,/[73_GTN?^^5_Q
MH]GYA[9=F']L)_SZW/\ WRO^-'L_,/;+LP_MA/\ GUN?^^5_QH]GYA[9=F']
ML)_SZW/_ 'R/\:/9^8>V79A_;$?_ #ZW'_?(_P :/9^8>V79B?VQ'_SZW'_?
M(_QH]GYA[==F']L1_P#/K<?]\C_&CV;[A[==F']L1_\ /K<?]\C_ !H]GYA[
M==F']LQ_\^MQ_P!\C_&CV?F'MUV8?VS'_P ^MQ_WR/\ &CV;[A[==F']LQ_\
M^MQ_WR/\:/9ON'MUV8?VS'_SZW'_ 'R/\:/9ON'MUV8?VS'_ ,^MQ_WR/\:/
M9ON'MUV8?VS%_P ^MQ_WR/\ &CV;[A[==F']M1?\^MQ_WR/\:/9ON'MUV8?V
MU%_SZW'_ 'R/\:/9ON'MUV8G]M1?\^UQ_P!\C_&CV;[B]NNS#^VHO^?:X_[Y
M'^-'LWW#VZ[,/[;B_P"?:X_[Y'^-'LWW#VZ[,/[;B_Y]KC_OD?XT>S?</;KL
MP_MN'_GVN/\ OD?XT>S?</;KLP_MN'_GVN/^^1_C1[-]P]NNS#^VX?\ GVN/
M^^1_C3]F^X>W79B?VY#_ ,^UQ_WR/\:/9ON'MUV8?VY#_P ^UQ_WR/\ &CV;
M[A]879A_;D/_ #[7'_?(_P :/9ON'UA=F']N0?\ /O<?]\C_ !H]F^X?6(]F
M']NP?\^]Q_WR/\:/9/N'UB/9A_;L'_/O<?\ ?(_QH]D^X?6(]F']NP?\^]Q_
MWR/\:/9/N'UB/9B?V[!_S[W'_?(_QH]D^X?6(]F']O0?\^]Q_P!\C_&CV3[A
M]8CV8?V];_\ /O<?]\C_ !H]D^X?6(]F']O6_P#S[W'_ 'R/\:/9/N+ZQ'LP
M_M^W_P"?>X_[Y'^-'LGW#ZQ'LP_M^W_YX7'_ 'R/\:/9/N'UB/9A_;]O_P \
M+C_OD?XT>R?</K$>S$_M^V_YX7'_ 'R/\:/9/N'UF/9A_P )!;?\\)_^^1_C
M1[)]P^LQ[,/^$@MO^>$__?(_QH]DP^LQ[,/^$@MO^>$__?(_QH]DP^LQ[,/^
M$@MO^>$__?(_QH]DP^LQ[,/^$AMO^>$__?(_QH]DP^LQ[,/^$AM?^>$__?(_
MQH]DP^LQ[,3_ (2&U_YXS_\ ?(_QH]DP^LQ[,/\ A(;7_GC/_P!\C_&CV3#Z
MS'LP_P"$AM?^>,__ 'R/\:/9,/K,>S#_ (2*U_YXS_\ ?(_QH]DP^LQ[,/\
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M#J-QJ/@RRN+JX,\NZ1/,,F_<%D91\V!NX Y[]:<EI%]TG^"#X92CV;(-&?\
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M*(Y<AB#G@@?0@4]TE_<O^"U!^[SM=):?^!/]/P*%A=WFB^%]';3)IV<:->W
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
I H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d140370d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cdtx-20210405.xsd" xlink:type="simple"/>
    <context id="duration_2021-04-05_to_2021-04-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-04-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2021-04-05_to_2021-04-05">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-04-05_to_2021-04-05"
      id="Hidden_dei_EntityCentralIndexKey">0001610618</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-04-05_to_2021-04-05">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-04-05_to_2021-04-05">2021-04-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-04-05_to_2021-04-05">Cidara Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-04-05_to_2021-04-05">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-04-05_to_2021-04-05">001-36912</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-04-05_to_2021-04-05">46-1537286</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-04-05_to_2021-04-05">6310 Nancy Ridge Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2021-04-05_to_2021-04-05">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-04-05_to_2021-04-05">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-04-05_to_2021-04-05">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-04-05_to_2021-04-05">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-04-05_to_2021-04-05">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-04-05_to_2021-04-05">752-6170</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-04-05_to_2021-04-05">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-04-05_to_2021-04-05">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-04-05_to_2021-04-05">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-04-05_to_2021-04-05">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-04-05_to_2021-04-05">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-04-05_to_2021-04-05">CDTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-04-05_to_2021-04-05">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-04-05_to_2021-04-05">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140491613719192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 05, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001610618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  05,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cidara Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-1537286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6310 Nancy Ridge Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">752-6170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CDTX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MJ%U_R/1L0FE0O&$43<NT*AD4S_3%'$Y@;WH>!1?X:=@;_HRA5"6"XKG]DP[
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *"5A5(D'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( *"5A5)ED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d140370d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d140370d8k.htm">d140370d8k.htm</File>
    <File>cdtx-20210405.xsd</File>
    <File>cdtx-20210405_lab.xml</File>
    <File>cdtx-20210405_pre.xml</File>
    <File>d140370dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d140370d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d140370d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cdtx-20210405_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cdtx-20210405_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cdtx-20210405.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cdtx",
   "nsuri": "http://imetrix.edgar-online.com/20210405",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d140370d8k.htm",
      "contextRef": "duration_2021-04-05_to_2021-04-05",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d140370d8k.htm",
      "contextRef": "duration_2021-04-05_to_2021-04-05",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20210405/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-21-106610-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-106610-xbrl.zip
M4$L#!!0    ( *"5A5*;9BHX; ,  #T,   1    8V1T>"TR,#(Q,#0P-2YX
M<V2]5M]OVS80?B_0_^&JIPV81,EIFEJ(4V1+ P1(L\%-A[T5M'1VB%&D1E*)
M_=_O2%FV8CNNDPS+2VC>?7??_:1./\TK"?=HK-!J%&5)&@&J0I="S4918V-N
M"R&B3V=OWYR^BV.XN+RZ@1CNG*MMSMC#PT-23H6R6C:.+-BDT!6#..[T?[O]
M!G^VUG,8HT1N$0;I((U/X-=&R#+W/[(L2Y.L#S/(O3THN<,<WK,/C/0R&.1'
M'_/C 9Q_@<_<.C0*;D6%?:2N%T;,[AS\5/P, 72AE4(I<0&70G%5""[A:T?X
M%[A210+G4L+8PRRQM&CNL4R65N>VS&UQAQ5_^P: TJ5LKLAD4XTBGX=E&N83
M(Q-M9JQTAKE%C8R48M)"(XJH!_TQ;@M#=? 2NP).N9T$4">A]&3#.,WBHZR'
M*THW7V$H3\Z(>8+EC)M8*RD4AG+Y)*7OT^,>L$2QP@6"%HMDIN\9"7:[\EIB
M=V"#-#UBU"..<H\]"!'X>P_"BR?4+GTG6Y"'HP#(AL,A"](-2J5[',?2^C%K
MA3UM*XK=(9/ AYSU0N:.,CEI'%YJ4UW@E#>2_#3JGX9+,158!BWJ]@J5>Z3S
M6,-Q,T-WPRNT-2_P1:6B]MR5$0HR8W]]N?X:.C<Z\P" T,RBJK5QT/;TM2["
MI.TIA/\5=_6+_56<#2@5"1F+0&VQWU-\8*\FTK7%BXBL>NI@(O:I"?"'>#T*
M3W'8-STOSL;FJO"Y&/I<9!\.RL76JOD/F&AU\UHRO7WY'$([I]4?XO78'E2>
MC4E_>8\H+HJPDD_:HR=R\@PB:_QK.Z6WZWQ=CO>ZWUR.2Z_!)U=*N^"HSX37
MM5!3O;RB2S]@>3=E8YQ"6,HY-X71$O>O;E8;7:-Q@IZS]:"V!NX,3D>1?\_B
M;@=^EWR2T [L5+8</!Y]+V8$07F]IM=AG7 >?.W%X.7T7<#ERK1OSU%D*>^R
MMSK^YW!K@\\-ER"67J!0MJ>C_J.G]>S@O9];T@!_^#:^^O$;MGK$F.-SK72U
M:,E>Z*+Q[V7W_UR5GQ517%Q1AYDJT(M T&LW)O7O!ZFOR'9T2Z2O51':.$O]
M'WW,=A;Z1ZY*:,U!S]XIVS2R:;^Q6/ZNSL*YX+)HY"KY2_!28Q]PLVR'(]?,
MGL8M;[O"=>/,-N=Y>=.?^_:JW3OT\U]02P,$%     @ H)6%4GVO7'^"!@
M2$<  !4   !C9'1X+3(P,C$P-# U7VQA8BYX;6S-G&UOVS80Q]\7Z'>X>6\V
MH+(C9T\QFA99'H9@21,T[C9L& I98FQB,FE0<FQ_^Y%Z:.28DJGP6.5%6T6Z
M^]_]E=^IC"3G[?OU/(8'(A+*V7'/[Q_T@+"01Y1-CWO+Q N2D-(>)&G HB#F
MC!SW-B3IO7_W^M7;;SP/SBXN/X 'LS1=)*/!8+5:]:-[RA(>+U,IF?1#/A^
MYY7QI^-/\$=>;@0?24R"A,#P8'C@_0R_+FD<C=07ON\?]/UJFB"!TH,H2,D(
M?AC\-)!Q/@Q'A[^,?AS"R36<!TE*!(,QG9-J)E]L!)W.4O@N_!ZRI#/.&(EC
MLH$+R@(6TB"&N[+A-W#)PCZ<Q#%\5&F)[#(AXH%$_4(UINR_D?IKHGJ'UZ\
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M.&LN:'1M[5Q;<]K($G[?JOT/4^1D"U=9( &^@"];7DRR;!S;!>S9U'E)#=(
M4Q&2=F9D8'_]Z1Y)W._&L$Z<JB02<^OI_KJGNV=&E[_VNRYY8D)RW[M*61DS
M19AG^P[WVE>I4+6,\Q3Y]?KGGRX["BI"94^6',:O4AVE@E(VVV\*-R.9G6G[
M3UDHR.9,JVB8EI&W4G'U4!IJ$# Y;-.BLIGQ13N;E,QIY/F>%W:'37J]7D8/
MA<T<);+8+@N5#*C%!+>3=GV7>]\FFO7RNI%5+!:SNC2I.E-S.$#.-/-9+&Y2
MR9+JMJ/ZP^J\RY3@_0QSVE08O@>56<;VN] T9YD%\V1(C^3SJ($1K.R7SW=U
MN\.ZU.">5-2SAV.%2BRDK)B%TJ0BEWXA9YTMF49<8]B@OZBN!77U/+[\5KL;
M55?SZX^J9I6@GFSYHDL5@ A[.C',G)$['>O$ (A,=)1 9E4_YV.8D-R>CSLH
MP.K6)(2P"E_&F2FF8ZDSA>RX\FDV*HRK+L87:DE*JPNC#OZON'+9];GQZ3(;
M/<)O@!U*L >#_1WRIZM4V?<4\Y31 %"GB!V]7:44ZZNL[I%DL5TV[I00<MGT
MG0$^7CK\B4@U<-E5RN$R<.D =8>EKLDE[Y>P!1/Q,W<<YD7/4.4^4ASBT2ZV
M9;QTTV6> W_5!Y>V8SKZJL9:4!P*+96OB&_#+!CFR5?EC[VEKEO4E>PR.]'Y
MS&#<N4K]KNGX"B-^K7C E$$9AA34K7H.ZW]B@]0820LJ;$B:"=IV:IFGUODL
M?=DIS@C68@),()/PCC:@)+6.PEA$FX\2FIZKE.3=P$7LZ-\Z DE!$V$D%B#3
METY23(4M?!31VM;F!>S8]65V<C[Q["=FK-^E'XKH5>M0*6:WEMX:[$Z:,2V\
MX2MW\(<69X)H$MA<@U"N?IH4V'1CI'IN_P%(U'>&KZ#<0MU2Q:Y'M"4M1V4C
M6IT%=9.2X;##<;(3W!ER<\2][+@&9D%3KR?T%5L9U.5MKV3#7)A(39;WN*,Z
MI?/,"?<NQNJZK*4NNE2TN6?@<XG04/G)+X*W._%/V%V0=(9FUN@P70K+?##L
M0OE!:>RUZ2OE=_4O35\ Z<DO5M GTG>Y0]Z9^D_J^I=WUJEY<9D-%@V47SU0
M;NN!QKHM0"=D=@*D!:(Q)/^'E:SSX7N+=KD[*#5@#9?DGO5(S>]2[T*7]2*Z
MF[[K7,P1SY_WU4;EEM0;-XU*?3$YYI[(J5?*?]:JC6JE3F[N;TGE2_GWF_N/
M%5)^^/RY6J]7'^Z?16-N%S3^164'G$GE>\?D-E/.D)QY4BA.T34UZ"ID3@)B
ME4;-1>;I5LC,F%!M$IP7D9;FK/>SLU]32T>328S$/(%%XM@#JCX\U#XO=A)N
M?3M$'V',5UE_(=9^T.0*_(:$%T'"3G07K$NM<M\@M<KC0ZUQ>%OR& H94D\1
MY9,ZLQ%LQ,H37Q#K).T<'9Y OT54AR%MH>"*0_M*W^Y0K\W(C:T(%%O%?&$Q
MG7N3+'HT2$Z-!;Y0))V\,PH>#9.*L">H280N9LY1:;5!>-1N427REC:U#"2*
M^ZY2$"N6'.B@"\T[#AT,@"+FI:YO L%=<G),L-&;#=F'#<D5=H&TA;B)0KL:
M:W.)D;^ZAY*-%Y0R=ZB@I-%A@@8L5-R6QZ3JV9D5$-G,-IB[8$2ZTJ=@ Y !
MJ&EB.'%")9$!LS&Z<0CW"%>2@-4 Q1/3-NT-V@N@_1S&8)J&-EU&;.:Z,J"V
M3GZ:*?T>4,=)WN.QXKG:ONO20+)2\K <(V. 0C<MXH9EFN]CWI7,F,R2F41O
M2)B(_G,F@\)\X3W&\\J9*GUB G2 NC%WHPG/K1GWD]N@GX3F^4VF.X1_8MI%
M4B6@;68T!:/?,.,)(7V)/OF D+499VG138Y+QM!$)N!4TD B4W,!3 "%(&9O
M CMCVKO2:(&!\06LC-HZU14L5V4_])08E'WG64L?IDDQ.:%8(/PG'!;7OEOF
MTAXL@[,V#6>Q 0P2S,_4?Q$>CA?W.EPQ W6+P0QZ8*Q7,OD#=QF4-<$V;9[O
MLXS\:='*+>38]\RX!NU7XVR9K3FU)1<+IX9UDC_+G9^NP<:7T/;S'2G[MNO^
M3J+IM+8/&*,\0&@@R!\0&4B'1\&+W]K(+[%>@+X)6Z;)%&WJ\7_T^U&TUAY&
M30XKMK+?[7*)VZ('%Q%:0A(I\0\LD&JFEJEG2*4;N/Z B8-+9=+&SLA'&T3X
M!QW+9T3[.PD]5BP8-XXCF)3Q?W?@_%L;+Q:G><LD]]2S!Z3&G38CMX(_S7@L
MQXO3"(M(R6U,2CV$)9-8YJHTP0%BP/5F7X;'!]'P>][F<P?/X9:SMK\MY_5J
M]2 >P?WD>F]\U\YL&3@"E3Q.5^T5+Z#PT8<^W?_Q8!MG^[J8LU;FC_Y-P$ L
MW( /M=5DT^<GYT>S;-[:O[SS845X[/C>MH[YV4G..+7.S(4.Y?9RV,TB$V-,
MYY#<$ -_ D@CR/UC0CV'-)C+ N1 ;/#':Z*<XJHZM9HD>'YY=YZSSBXD>12@
M4SR@+JGTF1TJL)#DH05+")-OB9Z7V0=9I9U@D#K,_J;3]C0 0Q4(COYZT^^3
M)G/]'N%13O\#&#9R;GPB+>ZBL+DD',_I.,S![0C)NZ&KJ,?\4+H#(D$39&N@
M6\8-_";P02N()/$^P5@.,(2.!"!LD)2U?!=&QX9H/3DZHK*T$"2G6^>\=I73
MLD8G!DKF6'9K-HLVE65;+VJ<#@2C 0KO+^8&V(L,V%^"*Y 9^O:A%WMN\MEK
M7-/WW28%<2E #7*Y>%8H7,S:N%5>^[23328E2IZ]$DT=(DE=Q_P !HPSA 1C
M^VRU$$!2R)W$")W:WL)=K;1U1LH?:B27-S-0<;4+_ ;;#6%;!_-J \.]]F>P
M36"@W!\8LR-F0-<1-V8!N]+'L0K4P/R@]CO&L#VQ7YL@>V5ON8*9B7H\&G-E
MWI1@ETKP*!C:;3RHJ,^?X-(KP'O:W W]CI1A)3*!:X8]QK8$\:LL_AH*Y!BY
M=/-HMRH4]?FF1'M2HJJ4(1-OJG1@5<HSHY"V=ZM*<9]KJ]+.XZHQ+S&*<YB
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MS.=ZI$2Q*BW?:4YZ^*@[*$?M]Q8:ORQWJJTER#P&/,Z%.9_9L.H B)D+$1R
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MSFK'#T[$\>1MG?SS@M1W5%C,[SG_O';N.-&3H0^R7.UB7%PV!;@U]WYFRX3
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M-# U+GAS9%!+ 0(4 Q0    ( *"5A5)]KUQ_@@8  $A'   5
M  "  9L#  !C9'1X+3(P,C$P-# U7VQA8BYX;6Q02P$"% ,4    " "@E852
M7K_A*,\$  #>+   %0              @ %0"@  8V1T>"TR,#(Q,#0P-5]P
M<F4N>&UL4$L! A0#%     @ H)6%4N282#<1#@  @U\   X
M ( !4@\  &0Q-# S-S!D.&LN:'1M4$L! A0#%     @ H)6%4DW>T]Z8)@
M9J,  !$              ( !CQT  &0Q-# S-S!D97@Y.3$N:'1M4$L%!@
0   %  4 0 $  %9$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
